Switch theme
Sign up to access all valuation multiples
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
2019
110
Last FY Revenue n/a
LTM EBITDA -$255M
-$133M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neumora Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$255M.
In the most recent fiscal year, Neumora Therapeutics achieved revenue of n/a and an EBITDA of -$263M.
Neumora Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neumora Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$255M | XXX | -$263M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$258M | XXX | -$263M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$243M | XXX | -$244M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Neumora Therapeutics's stock price is $1.
Neumora Therapeutics has current market cap of $116M, and EV of -$133M.
See Neumora Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$133M | $116M | XXX | XXX | XXX | XXX | $-1.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Neumora Therapeutics has market cap of $116M and EV of -$133M.
Neumora Therapeutics's trades at n/a EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Neumora Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neumora Therapeutics has a P/E ratio of -0.5x.
See valuation multiples for Neumora Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $116M | XXX | $116M | XXX | XXX | XXX |
| EV (current) | -$133M | XXX | -$133M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeumora Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.4M for the same period.
Neumora Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neumora Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neumora Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | -2% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neumora Therapeutics acquired XXX companies to date.
Last acquisition by Neumora Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Neumora Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Neumora Therapeutics founded? | Neumora Therapeutics was founded in 2019. |
| Where is Neumora Therapeutics headquartered? | Neumora Therapeutics is headquartered in United States of America. |
| How many employees does Neumora Therapeutics have? | As of today, Neumora Therapeutics has 110 employees. |
| Who is the CEO of Neumora Therapeutics? | Neumora Therapeutics's CEO is Mr. Paul L. Berns. |
| Is Neumora Therapeutics publicy listed? | Yes, Neumora Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Neumora Therapeutics? | Neumora Therapeutics trades under NMRA ticker. |
| When did Neumora Therapeutics go public? | Neumora Therapeutics went public in 2023. |
| Who are competitors of Neumora Therapeutics? | Similar companies to Neumora Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neumora Therapeutics? | Neumora Therapeutics's current market cap is $116M |
| Is Neumora Therapeutics profitable? | Yes, Neumora Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neumora Therapeutics? | Neumora Therapeutics's last 12 months EBITDA is -$255M. |
| What is the current EV/EBITDA multiple of Neumora Therapeutics? | Current EBITDA multiple of Neumora Therapeutics is 0.5x. |
| What is the current FCF of Neumora Therapeutics? | Neumora Therapeutics's last 12 months FCF is -$184M. |
| What is the current EV/FCF multiple of Neumora Therapeutics? | Current FCF multiple of Neumora Therapeutics is 0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
